

Rare diseases - the expanded clinical spectrum of hemophagocytic lymphohistiocytosis - Section 3

Treatment of hemophagocytic lymphohistiocytosis in adults

Nancy Berliner

Brigham and Women's Hospital, Boston, USA

Hemophagocytic lymphohistiocytosis (HLH) has traditionally been considered a disease of childhood, typically with a genetic cause ('familial HLH'), that occurs extremely rarely in the adult population. However, over the last 15-20 years there has been increasing recognition that HLH does occur in adults and almost always as *secondary HLH*; and as physicians become more aware of the diagnosis there is evidence that it is much less rare than originally assumed.¹ According to a large review on 2197 adult patients with HLH, the most common associated diseases are infections and neoplasms, with autoimmune diseases being the third most common.¹ Diagnosis and treatment of adult HLH has continued to be based almost entirely on the patterns defined in the pediatric population, that are focused on familial HLH. As more studies have been performed, there is growing recognition that the algorithms for diagnosis and treatment in children need to be modified for application to the adult population.²⁻⁶

Diagnostic criteria for HLH are somewhat more difficult to interpret in adults since many of the findings that are part of the diagnosis (fever, cytopenias, hyperferritinemia) are relatively non-specific, and some features may have different diagnostic implications in adult patients.⁷⁻⁹ Treatment paradigms also need to be re-evaluated in the adult setting. Since about half of adult HLH occurs in the setting of lymphoma,¹⁻⁶ treatment regimens may need to be tailored to therapy of the inciting malignancy, but the adjustments in therapy targeting HLH per se remain controversial.¹⁰ For patients with infection-associated and idiopathic adult HLH, pediatric dosing of HLH therapy may not be suitable for the treatment of older patients.¹¹ In the end, the role of stem cell transplantation in adult HLH requires evaluation in the light of the unique features differentiating adult from pediatric disease, the relative risk of transplant, and the nature of the disease trigger.¹²

References

1. Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, et al. Adult haemophagocytic syndrome. *Lancet*. 2014;383:1503-16.
- *2. Parikh SA, Kapoor P, Letendre L, et al. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. *Mayo Clin Proc*. 2014;89:484-92.
- This is a large report on a series of adults with HLH.*
3. Nikiforow S, Berliner N. The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults. *Hematology Am Soc Hematol Educ Program*. 2015;2015:183-9.
4. Otrrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. *Am J Hematol*. 2015;90:220-4.
5. Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. *Br J Haematol*. 2016;172:412-9.
6. Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. *Int J Hematol*. 2007;86:58-65.
- *7. Schram AM, Campigotto F, Mullally A, et al. Marked hyperferritinemia does not predict for HLH in the adult population. *Blood*. 2015;125:1548-52.
- This study reports that the specificity of hyperferritinemia for HLH in adults is much less than in children.*
- *8. Tsuji T, Hirano T, Yamasaki H, et al. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. *Ann Hematol*. 2014;93:821-6.
- This report suggests that markedly elevated sIL-2R is highly predictive of lymphoma-associated HLH, which is seen primarily in adult patients.*
9. Tabata C, Tabata R. Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndrome. *Ann Hematol*. 2012;91:63-71.
10. Lehmborg K, Nichols KE, Henter JI, et al. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. *Haematologica*. 2015;100:997-1004.
- *11. La Rosee P. Treatment of hemophagocytic lymphohistiocytosis in adults. *Hematology Am Soc Hematol Educ Program*. 2015;2015:190-6.
- This paper reviews the unique aspects of therapy of HLH in adults.*
- *12. Nikiforow S. The Role of Hematopoietic Stem Cell Transplantation in Treatment of Hemophagocytic Lymphohistiocytosis. *Hematol Oncol Clin North Am*. 2015;29:943-59.
- This review outlines the unique challenges of stem cell transplantation in adults with HLH.*